000064496 001__ 64496
000064496 005__ 20190709135527.0
000064496 0247_ $$2doi$$a10.1002/cpt.639
000064496 0248_ $$2sideral$$a97965
000064496 037__ $$aART-2017-97965
000064496 041__ $$aeng
000064496 100__ $$aPatrignani, P
000064496 245__ $$aLow-dose aspirin acetylates cyclooxygenase-1 in human colorectal mucosa: implications for the chemoprevention of colorectal cancer.
000064496 260__ $$c2017
000064496 5060_ $$aAccess copy available to the general public$$fUnrestricted
000064496 5203_ $$aThe mechanism of action of low-dose aspirin in the prevention of colorectal cancer (CRC) remains largely hypothetical. We aimed to compare the effects of low-dose aspirin (100 mg/day for 7 days) given to 40 individuals undergoing CRC screening on the extent of cyclooxygenase (COX)-1 acetylation at serine-529 (AceCOX-1), in blood platelets vs colorectal mucosa, at 7 (group 1) and 24 hours (group 2) after dosing. A significantly (P<0.01) lower %AceCOX-1 was detected in colonic and rectal mucosa (average 64%) vs platelets (average 75%) in both groups. This effect was associated with an average 46% (P<0.01) and 35% (P<0.05) reduction in prostaglandin (PG) E2 levels and phosphorylated S6 (p-S6) levels, respectively. Rectal mucosal levels of p-S6/S6 significantly(P<0.01) correlated with PGE2. These findings demonstrate that low-dose aspirin produces long-lasting acetylation of COX-1 and down-regulation of p-S6 in human colorectal mucosa, an effect that may interfere with early colorectal carcinogenesis.
000064496 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000064496 590__ $$a6.544$$b2017
000064496 591__ $$aPHARMACOLOGY & PHARMACY$$b13 / 261 = 0.05$$c2017$$dQ1$$eT1
000064496 592__ $$a1.699$$b2017
000064496 593__ $$aPharmacology (medical)$$c2017$$dQ1
000064496 593__ $$aPharmacology$$c2017$$dQ1
000064496 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000064496 700__ $$aSacco, A
000064496 700__ $$aSostres, C
000064496 700__ $$aBruno, A
000064496 700__ $$aDovizio, M
000064496 700__ $$0(orcid)0000-0001-5813-3445$$aPiazuelo, E$$uUniversidad de Zaragoza
000064496 700__ $$aDi Francesco, L
000064496 700__ $$aContursi, A
000064496 700__ $$aZucchelli, M
000064496 700__ $$aSchiavone, S
000064496 700__ $$aTacconelli, S
000064496 700__ $$aPatrono, C
000064496 700__ $$0(orcid)0000-0001-5932-2889$$aLanas, A.$$uUniversidad de Zaragoza
000064496 7102_ $$11005$$2410$$aUniversidad de Zaragoza$$bDpto. Farmacología y Fisiolog.$$cÁrea Fisiología
000064496 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000064496 773__ $$g36 (2017), [29 pp.]$$pClin. pharmacol. ther.$$tCLINICAL PHARMACOLOGY & THERAPEUTICS$$x0009-9236
000064496 8564_ $$s862975$$uhttps://zaguan.unizar.es/record/64496/files/texto_completo.pdf$$yPostprint
000064496 8564_ $$s116758$$uhttps://zaguan.unizar.es/record/64496/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000064496 909CO $$ooai:zaguan.unizar.es:64496$$particulos$$pdriver
000064496 951__ $$a2019-07-09-12:00:16
000064496 980__ $$aARTICLE